1. Home
  2. VNDA vs UIS Comparison

VNDA vs UIS Comparison

Compare VNDA & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNDA
  • UIS
  • Stock Information
  • Founded
  • VNDA 2002
  • UIS 1942
  • Country
  • VNDA United States
  • UIS United States
  • Employees
  • VNDA N/A
  • UIS N/A
  • Industry
  • VNDA Biotechnology: Pharmaceutical Preparations
  • UIS EDP Services
  • Sector
  • VNDA Health Care
  • UIS Technology
  • Exchange
  • VNDA Nasdaq
  • UIS Nasdaq
  • Market Cap
  • VNDA 249.4M
  • UIS 260.2M
  • IPO Year
  • VNDA 2006
  • UIS N/A
  • Fundamental
  • Price
  • VNDA $4.41
  • UIS $2.70
  • Analyst Decision
  • VNDA Strong Buy
  • UIS Buy
  • Analyst Count
  • VNDA 3
  • UIS 4
  • Target Price
  • VNDA $14.00
  • UIS $5.88
  • AVG Volume (30 Days)
  • VNDA 682.0K
  • UIS 633.6K
  • Earning Date
  • VNDA 10-29-2025
  • UIS 11-05-2025
  • Dividend Yield
  • VNDA N/A
  • UIS N/A
  • EPS Growth
  • VNDA N/A
  • UIS N/A
  • EPS
  • VNDA N/A
  • UIS N/A
  • Revenue
  • VNDA $212,074,000.00
  • UIS $1,921,000,000.00
  • Revenue This Year
  • VNDA $14.32
  • UIS $0.98
  • Revenue Next Year
  • VNDA $37.05
  • UIS $2.56
  • P/E Ratio
  • VNDA N/A
  • UIS N/A
  • Revenue Growth
  • VNDA 11.12
  • UIS N/A
  • 52 Week Low
  • VNDA $3.81
  • UIS $2.63
  • 52 Week High
  • VNDA $5.70
  • UIS $8.93
  • Technical
  • Relative Strength Index (RSI)
  • VNDA 34.91
  • UIS 20.64
  • Support Level
  • VNDA $4.32
  • UIS $3.42
  • Resistance Level
  • VNDA $4.51
  • UIS $3.60
  • Average True Range (ATR)
  • VNDA 0.23
  • UIS 0.14
  • MACD
  • VNDA -0.13
  • UIS -0.07
  • Stochastic Oscillator
  • VNDA 9.44
  • UIS 5.66

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.

Share on Social Networks: